Vimarsana
Biggest News Aggregation in the World

Page 10 - Thomas Triomphe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomas Triomphe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomas Triomphe Today - Breaking & Trending Today

Stock Market | FinancialContent Business Page - Vimarsana News

Stock Market | FinancialContent Business Page

FinancialContent fully hosted finance channel

FDA staff appear supportive of RSV drug from AstraZeneca, Sanofi - Vimarsana News

FDA staff appear supportive of RSV drug from AstraZeneca, Sanofi

BioPharma

RWE shows efficacy of nirsevimab for infant RSV - Vimarsana News

RWE shows efficacy of nirsevimab for infant RSV

New real-world data “adds to the evidence that use of long-acting mAb [nirsevimab] may prevent moderate to severe RSV disease” in infants.

Nirsevimab delivers 83 percent reduction in RSV infant hospitalizations in a real world clinical trial setting: Sanofi - Vimarsana News

Nirsevimab delivers 83 percent reduction in RSV infant hospitalizations in a real world clinical trial setting: Sanofi

RSV is the most common cause of LRTD, including bronchiolitis and pneumonia, in infants.

Sanofi's RSV vaccine reduces infant hospitalizations by 83% - Vimarsana News

Sanofi's RSV vaccine reduces infant hospitalizations by 83%

A target action date for the FDA is expected in Q3 2023 and if greenlit, Sanofi’s nirsevimab would be the first broadly-approved RSV vaccine for children.